Literature DB >> 35945356

The need to consider return to work as a main outcome in patients undergoing surgery for diffuse low-grade glioma: a systematic review.

Juan Silvestre G Pascual1, Hugues Duffau2,3.   

Abstract

OBJECTIVE: For a long time, return to work (RTW) has been neglected in patients harboring a diffuse low-grade glioma (LGG). However, a majority of LGG patients worked at time of diagnosis. Moreover, these patients now live longer given current treatment paradigms, especially thanks to early maximal surgery.
METHODS: We systematically searched available medical databases for studies that reported data on RTW in patients who underwent resection for LGG.
RESULTS: A total of 30 studies were selected: 19 considered RTW (especially rate and timing) as an outcome and 11 used scales of health-related quality of life (HRQoL) which included work-related aspects. Series that considered RTW as a main endpoint were composed of 1014 patients, with postoperative RTW rates ranging from 31 to 97.1% (mean 73.1%). Timing to RTW ranged from 15 days to 22 months (mean 6.3 months). Factors related to an increased proportion of RTW were: younger age, better neurologic status, having a white-collar occupation, working pre-operatively, being the sole breadwinner, the use of awake surgery, and greater extent of resection. Female sex, older age, poor neurologic status, pre-operative history of work absences, slow lexical access speed, and postoperative seizures were negatively related to RTW. No studies that used HRQoL scales directly investigated RTW rate or timing.
CONCLUSIONS: RTW was scarcely analyzed in LGG patients who underwent resection. However, because they are usually young, with no or only mild functional deficits and have a longer life expectancy, postoperative RTW should be assessed more systematically and accurately as a main outcome. As majority (61.5-100%) of LGG patients were working at time of surgery, the responsibility of neurosurgeons is to bring these patients back to their previous activities according to his/her wishes. RTW might also be included as a critical endpoint for future prospective studies and randomized control trials on LGGs.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Functional outcome; Low-grade glioma; Return to work; Socio-economics; Surgery

Mesh:

Year:  2022        PMID: 35945356     DOI: 10.1007/s00701-022-05339-y

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.816


  69 in total

1.  Health-related quality of life in stable, long-term survivors of low-grade glioma.

Authors:  Florien W Boele; Linda Douw; Jaap C Reijneveld; Rianne Robben; Martin J B Taphoorn; Neil K Aaronson; Jan J Heimans; Martin Klein
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  Compromised health-related quality of life in patients with low-grade glioma.

Authors:  Neil K Aaronson; Martin J B Taphoorn; Jan J Heimans; Tjeerd J Postma; Chad M Gundy; Guus N Beute; Ben J Slotman; Martin Klein
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

3.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Authors:  Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran
Journal:  N Engl J Med       Date:  2016-04-07       Impact factor: 91.245

Review 4.  Return to work after a cancer diagnosis: a meta-review of reviews and a meta-synthesis of recent qualitative studies.

Authors:  Phyllis Butow; Rebekah Laidsaar-Powell; Stephanie Konings; Chloe Yi Shing Lim; Bogda Koczwara
Journal:  J Cancer Surviv       Date:  2019-12-19       Impact factor: 4.442

5.  Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article.

Authors:  Laurent Capelle; Denys Fontaine; Emmanuel Mandonnet; Luc Taillandier; Jean Louis Golmard; Luc Bauchet; Johan Pallud; Philippe Peruzzi; Marie Hélène Baron; Michèle Kujas; Jacques Guyotat; Remi Guillevin; Marc Frenay; Sophie Taillibert; Philippe Colin; Valérie Rigau; Fanny Vandenbos; Catherine Pinelli; Hugues Duffau
Journal:  J Neurosurg       Date:  2013-03-15       Impact factor: 5.115

6.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.

Authors:  M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

7.  Work functioning trajectories in cancer patients: Results from the longitudinal Work Life after Cancer (WOLICA) study.

Authors:  Heleen F Dorland; Femke I Abma; Corné A M Roelen; Roy E Stewart; Benjamin C Amick; Adelita V Ranchor; Ute Bültmann
Journal:  Int J Cancer       Date:  2017-07-19       Impact factor: 7.396

8.  Recession, employment and self-rated health: a study on the gender gap.

Authors:  I Aguilar-Palacio; P Carrera-Lasfuentes; R Sánchez-Recio; J P Alonso; M J Rabanaque
Journal:  Public Health       Date:  2017-12-01       Impact factor: 2.427

9.  Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.

Authors:  Linda Dirven; Jammbe Z Musoro; Corneel Coens; Jaap C Reijneveld; Martin J B Taphoorn; Florien W Boele; Mogens Groenvold; Martin J van den Bent; Roger Stupp; Galina Velikova; Kim Cocks; Mirjam A G Sprangers; Madeleine T King; Hans-Henning Flechtner; Andrew Bottomley
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

10.  The Work Role Functioning Questionnaire v2.0 Showed Consistent Factor Structure Across Six Working Samples.

Authors:  Femke I Abma; Ute Bültmann; Benjamin C Amick Iii; Iris Arends; Heleen F Dorland; Peter A Flach; Jac J L van der Klink; Hardy A van de Ven; Jakob Bue Bjørner
Journal:  J Occup Rehabil       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.